Mission and Vision

The overall mission of the Wound Care Collaborative Community (WCCC) is to assure that patients and health care professionals have access to safe, effective, and high-quality medical devices and drugs to treat chronic wounds.

The WCCC will work in the pre-competitive space* to identify methods, tools, approaches and appropriate clinical evidence that will enhance understanding and improve evaluation of product safety, quality, and effectiveness.

The WCCC initiatives aim to improve product safety and patient access to cutting-edge medical technology while reducing cost and time to market.

The WCCC aims to accelerate the development of science-based patient-centered solutions and address public policy challenges related to assuring patients receive early access to innovative treatment options.

* Pre-competitive collaboration is where two (or more) potential competing companies work together toward a common goal. Regardless of how the pre-competitive collaboration starts, the outcome is for the entire industry.

FDA Collaborative Communties

A collaborative community is a continuing forum in which private- and public-sector members, which can include the FDA, work together on medical device challenges to achieve common objectives and outcomes. Participation in collaborative communities was one of the FDA’s Center for Devices and Radiological Health’s (CDRH) strategic priorities for 2018-2020.

How We Got Here



Engaged with FDA

  • Defined issues
  • Develop strategy
  • Collaborated on methods

Launched WEF-CEP

  • 28 relevant endpoints

Developed Clinician survey

  • WC advisory team


Completed Clinician Survey

  • Presented to FDA
  • Published results

Completed Evidence Research for 15 Endpoints

  • Presented to FDA
  • Published results


Completed Patient Survey

  • Published Results

Submitted Final Endpoints

Recommendations to FDA

Presented evidence FDA-CPIM

WCCC Charter developed and submitted to FDA